{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:35:16Z","timestamp":1793432116133,"version":"4.5.0"},"reference-count":16,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"abstract":"\n Importance<\/jats:title>\n Neoadjuvant nivolumab plus ipilimumab in localized deficient mismatch repair\/microsatellite instability\u2013high gastric or gastroesophageal junction (GEJ) adenocarcinoma was evaluated in the NEONIPIGA study. The primary end point of pathological complete response (pCR) was previously reported.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To report long-term follow-up results and secondary end points, including event-free survival (EFS) and overall survival (OS), of the NEONIPIGA study.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The NEONIPIGA study is a French, multicenter, single-arm, phase 2 nonrandomized clinical trial that included patients with histologically proven cT2-T4NXM0 deficient mismatch repair\/microsatellite instability\u2013high GEJ adenocarcinoma who were eligible for surgery. Patients were enrolled between October 23, 2019, and June 4, 2021, and the database was locked on November 13, 2025.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Neoadjuvant nivolumab, 240 mg, every 2 weeks for 6 cycles plus ipilimumab, 1 mg\/kg, every 6 weeks for 2 cycles, followed by surgery 5 weeks after the last nivolumab dose, and adjuvant nivolumab, 480 mg, every 4 weeks for 9 cycles.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n EFS and OS.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 32 patients (median [range] age, 65 [40-80] years; 8 [28%] female and 21 [72%] were male) were included: 16 (50%) with gastric cancer and 16 (50%) with GEJ cancer. Three patients did not undergo surgery (1 with metastatic disease and 2 who refused). Twenty-seven patients (84%) completed neoadjuvant therapy and 14 (44%) received all treatment as planned. Neoadjuvant and adjuvant therapy-related grade 3\/4 adverse events occurred in 6 (19%) and 4 patients (17%), respectively. Median follow-up was 48.3 months (95% CI, 44.8-52.0 months). Among the 32 patients in the intention-to-treat population, 4-year OS was 84.1% (95% CI, 65.8%-93.0%). In the 31 patients eligible for surgery, 4-year EFS was 83.5% (95% CI, 64.8%-92.8%). One patient relapsed with cerebral metastases. Six deaths occurred: 2 related to gastric cancer or treatment (1 patient had postoperative complications and 1 cerebral metastases) and 4 unrelated. All patients who did not undergo surgery achieved a clinical complete response after immune checkpoint inhibitor therapy. One patient subsequently died of causes unrelated to their cancer. Overall, 17 of 29 patients (59%) achieved pCR on surgical specimen. Safety was previously reported, and no additional late toxic effects were observed.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this phase 2 nonrandomized clinical trial, the immunotherapy regimen evaluated was associated with sustained long-term survival, but no clear evidence of improved survival over outcomes reported in other studies evaluating surgery alone in this patient population was observed. The high pCR rates and durable responses observed may provide useful information for designing future clinical studies, including randomized trials investigating organ-preserving strategies.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04006262<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.4162","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:36Z","timestamp":1792076436000},"source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab-Ipilimumab for Localized Microsatellite Instability\u2013High Gastric\/Gastroesophageal Junction Adenocarcinoma"],"prefix":"10.1001","author":[{"given":"Thomas","family":"Samaille","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, INSERM 938, SIRIC CURAMUS, Paris, France"},{"name":"Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Henriques","sequence":"additional","affiliation":[{"name":"Methodology and Quality of Life Unit in Oncology, University of Besan\u00e7on, Besan\u00e7on, France"},{"name":"Universit\u00e9 Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Poitiers University Hospital, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Piessen","sequence":"additional","affiliation":[{"name":"Department of Digestive and Oncological Surgery, University of Lille, CNRS, INSERM, CHU Lille, UMR9020-U1366\u2013ONCOLille\u2013CRCLille\u2013 Team PancRestT, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institute Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Louvet","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Adenis","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), INSERM, University of Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Jary","sequence":"additional","affiliation":[{"name":"Department of Digestive Oncology, University Hospital Clermont-Ferrand, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Line","family":"Garcia-Larnicol","sequence":"additional","affiliation":[{"name":"GERCOR, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, INSERM 938, SIRIC CURAMUS, Paris, France"},{"name":"Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[{"name":"Methodology and Quality of Life Unit in Oncology, University of Besan\u00e7on, Besan\u00e7on, France"},{"name":"Universit\u00e9 Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie H.","family":"Lefevre","sequence":"additional","affiliation":[{"name":"Sorbonne University, Paris, France"},{"name":"Department of Digestive Surgery, Saint-Antoine Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Svrcek","sequence":"additional","affiliation":[{"name":"Department of Pathology, L\u00e9on B\u00e9rard Comprehensive Cancer Center, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, INSERM 938, SIRIC CURAMUS, Paris, France"},{"name":"Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"3","key":"coi260058r1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer.","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"coi260058r2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN Clinical Practice Guidelines in Oncology.","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"35","key":"coi260058r3","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi260058r4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study.","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi260058r5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"coi260058r6","doi-asserted-by":"publisher","first-page":"CT230","DOI":"10.1158\/1538-7445.AM2026-CT230","article-title":"Abstract CT230: STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of microsatellite instability-high (MSI-H) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC): final results of the cohort 2 of INFINITY study by GONO GI.","volume":"86","author":"Leone","year":"2026","journal-title":"Cancer Res"},{"issue":"10","key":"coi260058r7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.dld.2022.07.008","article-title":"Immunotherapy in MSI\/dMMR tumors in the perioperative setting: the IMHOTEP trial.","volume":"54","author":"Coutzac","year":"2022","journal-title":"Dig Liver Dis"},{"key":"coi260058r8","doi-asserted-by":"publisher","first-page":"S899","DOI":"10.1016\/j.annonc.2024.08.1514","article-title":"1448P IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR\/MSI localized cancers: results of the digestive non-colorectal cancer cohorts.","volume":"35","author":"Fouchardiere","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"coi260058r9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis.","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi260058r10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010598","article-title":"Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors.","volume":"13","author":"Nasca","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"29","key":"coi260058r11","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO-25-00486","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase III KEYNOTE-585 study.","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi260058r12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial.","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"32","key":"coi260058r13","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO-25-00447","article-title":"Neoadjuvant CTLA-4\/PD-(L)1 blockade versus surgery +\/- chemotherapy in deficient mismatch repair\/microsatellite instability-high resectable gastroesophageal adenocarcinoma: individual patient data pooled analysis.","volume":"43","author":"Raimondi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"23","key":"coi260058r14","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors.","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"key":"coi260058r15","unstructured":"Study of induction PD-1 blockade in subjects with locally advanced mismatch repair deficient solid tumors. ClinicalTrials.gov identifier: NCT04165772. Updated September 15, 2026. Accessed September 21, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04165772"},{"key":"coi260058r16","unstructured":"Watch-and-wait with dostarlimab in localized dMMR\/MSI-H gastric\/GEJ adenocarcinoma phase II study (DEWI). ClinicalTrials.gov identifier: NCT06059495. Updated August 26, 2026. Accessed September 21, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06059495"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2855333\/jamaoncology_samaille_2026_oi_260058_1791401372.29043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:37Z","timestamp":1792076437000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2855333"}},"subtitle":["The Phase 2 NEONIPIGA Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.4162","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}